Negligent blood transfusion — when the hospital is strictly liable

A patient who contracts hepatitis-C or HIV from a blood transfusion is not in the doctrinal position of a patient complaining of a surgical slip. Blood is a "drug" within the meaning of Section 3(b) of the Drugs and Cosmetics Act, 1940; a blood bank is a licensed establishment under Schedule F Part XIIB of the Drugs and Cosmetics Rules, 1945; donor screening for HIV-I and II, hepatitis-B, hepatitis-C, syphilis and malaria is mandatory under that Schedule and under the NACO Standards for Blood Banks made operational after the Supreme Court's directions in Common Cause v Union of India, (1996) 1 SCC 753. Where untested or improperly tested blood is released and a transfusion-transmissible infection results, the liability runs on two doctrinal tracks at once — the strict-liability spine of Rylands v Fletcher, (1868) LR 3 HL 330 as carried into India through M C Mehta v Union of India, (1987) 1 SCC 395 and Indian Council for Enviro-Legal Action v Union of India, (1996) 3 SCC 212, and the Bolam test as adopted for India in Jacob Mathew v State of Punjab, (2005) 6 SCC 1, which calibrates the treating doctor's separate duty. This guide sets out the statutory architecture, the doctrinal frame, and the compensation calculus the consumer forums and the Supreme Court have applied.

India has run a regulated blood-transfusion service since the Supreme Court's directions in Common Cause v Union of India, (1996) 1 SCC 753 — directions that retrofitted a statutory architecture onto an unlicensed and largely professional-donor-driven sector. The architecture rests on three legs. The first leg is the Drugs and Cosmetics Act, 1940 — Section 3(b) defines "drug" to include any substance intended for use in the diagnosis, treatment, mitigation or prevention of disease, and the Supreme Court in Common Cause held that human whole blood, blood components and blood products fall squarely within that definition. The second leg is Schedule F Part XIIB of the Drugs and Cosmetics Rules, 1945, which lays down the "Requirements for the Functioning and Operation of a Blood Bank" — donor selection criteria, mandatory screening for HIV-I and II, hepatitis-B, hepatitis-C, syphilis and malaria, equipment specifications, record-keeping, qualified personnel. The third leg is the National Blood Transfusion Council and the State Blood Transfusion Councils, created on the Common Cause directions, and the operational guidelines now issued by the National AIDS Control Organisation. When a transfusion infects, the question is not only whether the doctor met the Bolam standard. It is whether the blood bank discharged a strict-liability duty that the law imposes on the handler of a dangerous substance.

Blood is a "drug" — the statutory anchor

Section 3(b) of the Drugs and Cosmetics Act, 1940 defines "drug" to include "all substances intended to be used for or in the diagnosis, treatment, mitigation or prevention of any disease or disorder in human beings or animals". The definition is functional and intentionally wide. The Supreme Court in Common Cause v Union of India, (1996) 1 SCC 753 — a public-interest petition prompted by widespread HIV transmission through blood transfusions in the late 1980s and early 1990s — held that whole human blood and its components are substances intended for use in the treatment of disease and therefore fall within Section 3(b). The consequence was immediate. A blood bank manufactures, stores and sells a "drug"; under Sections 18, 18A and 18B of the Drugs and Cosmetics Act, 1940, no person can manufacture, sell or distribute a drug except under a licence issued by the State Drugs Controller; and under Section 27 of the Act, any contravention is punishable, in aggravated cases, with imprisonment that the statute fixes at not less than three years and which may extend to life imprisonment where the substandard drug results in death or grievous hurt.

Schedule F Part XIIB of the Drugs and Cosmetics Rules, 1945 operationalises the licensing regime for blood banks. It is the technical heart of the regulatory architecture and the document that every consumer forum looks at first when a transfusion-infection complaint is filed. Part XIIB lays down — donor selection criteria including the deferral periods, mandatory pre-donation screening for HIV-I and HIV-II, hepatitis-B surface antigen, hepatitis-C virus, syphilis (VDRL) and malaria, the equipment and reagents the bank must maintain, the qualifications of the medical officer in charge and the technical staff, the record-keeping requirements including the bag number, donor identification, screening results and the recipient details, and the cold-chain and storage requirements. A blood bank that fails to screen, fails to record or fails to maintain the cold chain operates outside the conditions of its licence. The licence becomes a statutory yardstick — a breach of Part XIIB is, in working language, a breach of statutory duty actionable on the same evidential basis on which any breach of regulatory licensing conditions is actionable.

The National AIDS Control Organisation under the Ministry of Health and Family Welfare publishes the Standards for Blood Banks and Blood Transfusion Services, which expand on Part XIIB with operational protocols — the testing algorithm, the confirmatory-test escalation for reactive samples, the protocols for component preparation, and the look-back and recipient-notification procedures where a donor is found infected on a later donation. The National Blood Transfusion Council and the State Blood Transfusion Councils, set up on the Common Cause directions in 1996, are the policy bodies under which the NACO standards operate. A consumer forum or a writ court hearing a transfusion-infection complaint reads Part XIIB and the NACO Standards together — the former as binding subordinate legislation, the latter as operational standard against which "due diligence" is measured.

Common Cause v Union of India — the architecture the Court built

The directions in Common Cause v Union of India, (1996) 1 SCC 753 were a doctrinal landmark and a regulatory retrofitting in one. The petition disclosed that a large number of blood banks were operating without licences under the Drugs and Cosmetics Act, 1940; that professional donation — where a donor sells blood for cash, repeatedly, often with a history of intravenous drug use or sex work — was widespread; that screening was patchy where it existed at all; and that hepatitis-C and HIV were being transmitted through transfusions at a rate that was not consistent with a regulated medical service. The Court, hearing the petition under Article 32, did three things. First, it held that the Drugs and Cosmetics Act, 1940 applied to blood and blood products and that every blood bank required a licence under that Act. Second, it directed the Government of India to establish a National Blood Transfusion Council and State Blood Transfusion Councils and to phase out professional donation by a fixed date — a deadline the Court itself enforced through compliance orders. Third, it directed mandatory screening of all collected blood for HIV-I and II, hepatitis-B, hepatitis-C, syphilis and malaria, and directed the gradual upgrading of the country's blood banks to meet that screening standard.

The directions in Common Cause have since been treated as having the force of statute. They were given effect through amendments to the Drugs and Cosmetics Rules, 1945 — Schedule F Part XIIB in its present form is the codification of the Common Cause regime — and through the creation of the NBTC, the SBTCs and the NACO Standards. A consumer forum or a high court hearing a transfusion-infection complaint after 1998 reads the Common Cause directions, Schedule F Part XIIB and the NACO Standards as a single regulatory composite. A blood bank that did not screen for hepatitis-C in 2002, or that did not phase out professional donation by the date the Court fixed, is a blood bank that breached the regulatory architecture the Supreme Court itself built. That breach is the doctrinal hinge on which the strict-liability analysis turns.

Strict liability — Rylands, M C Mehta and the no-fault spine

The doctrinal frame for "no-fault" liability in Indian tort law begins with the House of Lords decision in Rylands v Fletcher, (1868) LR 3 HL 330. The defendant got a reservoir constructed over disused mine shafts; the water burst through the shafts and flooded the plaintiff's adjoining coal-mine; the defendant was held liable even though he had not been negligent and the contractors had been. Blackburn J in the Exchequer Chamber framed the rule as one of strict liability for the escape of a "dangerous thing" brought onto the defendant's land for the defendant's own purposes; the House of Lords added the "non-natural user" qualification. The rule has been applied in Indian decisions for over a century — to escapes of gas, electricity, explosives, noxious fumes and water — and was extended by the Kerala High Court in T C Balakrishnan Menon v T R Subramanian to firework explosives even where the work was done by an independent contractor.

The Supreme Court in M C Mehta v Union of India, (1987) 1 SCC 395 — the oleum-gas-leak case, decided a year after the Bhopal disaster — refused to be "constrained" by the nineteenth-century Rylands rule and evolved a stricter rule of "absolute liability" for enterprises engaged in hazardous or inherently dangerous activity. The principle Bhagwati CJ laid down was that "where an enterprise is engaged in a hazardous or inherently dangerous activity and harm results to anyone on account of an accident in the operation of such hazardous or inherently dangerous activity resulting, for example, in the escape of toxic gas, the enterprise is strictly and absolutely liable to compensate all those who are affected by the accident and such liability is not subject to any of the exceptions which operate vis-a-vis the tortious principle of strict liability under the rule in Rylands v Fletcher." The Supreme Court in Indian Council for Enviro-Legal Action v Union of India, (1996) 3 SCC 212 — the Bichhri industrial-pollution case — applied M C Mehta and held the polluting industries absolutely liable on the "Polluter Pays" principle to fund the restoration of the soil, water and environment.

The doctrinal question whether the Rylands rule, or the stricter M C Mehta rule, applies to a blood bank is one on which the consumer forums and the high courts have not always spoken with one voice. The defensible view is that blood collection, processing and transfusion is an "inherently dangerous" activity in the M C Mehta sense — the substance is biologically hazardous if mis-handled, the consequences of escape (an unscreened unit transfused into a recipient) are irreversible, and the risk is one the enterprise alone is positioned to control. On that view, a blood bank that releases an infected unit is absolutely liable, without recourse to the Rylands exceptions (act of God, act of a stranger, plaintiff's default), provided the harm is causally linked to the unit released. On a narrower view, the Rylands rule applies and the bank can plead, for example, that the donor concealed material facts (act of a stranger) — though the very design of Schedule F Part XIIB, which makes the screening of the donated unit mandatory regardless of donor history, makes this defence difficult to mount. The practical position before the consumer forums has been that the bank is liable for the unit it released; the doctrinal label — strict or absolute — affects the availability of defences but not the broad outcome.

The Bolam-Jacob Mathew layer — the treating doctor's standard

Strict-liability analysis governs the blood bank. The treating doctor's liability is calibrated separately, on the Bolam test as adopted for India by the three-judge Bench of the Supreme Court in Jacob Mathew v State of Punjab, (2005) 6 SCC 1. The Bolam standard — laid down by McNair J in Bolam v Friern Hospital Management Committee, [1957] 1 WLR 582 — is that the doctor is not negligent if he has acted in accordance with a practice accepted as proper by a responsible body of medical opinion. Jacob Mathew adopted Bolam for civil and consumer-forum liability and fixed a higher gross-negligence threshold for criminal prosecution under Section 106(1) of the Bharatiya Nyaya Sanhita, 2023 [Section 304A IPC]. Kusum Sharma v Batra Hospital and Medical Research Centre, (2010) 3 SCC 480 distilled the position into eleven working principles.

What the Bolam-Jacob Mathew layer adds in a transfusion-infection case is a separate set of duties on the treating doctor and the hospital. The doctor must have a clinical indication for the transfusion — transfusing blood unnecessarily, where a saline or volume expander would have sufficed, is itself a breach. The doctor must obtain consent that discloses the residual risk of transfusion-transmitted infection; Samira Kohli v Dr Prabha Manchanda, (2008) 2 SCC 1 read the doctrine of informed consent into the Bolam framework and held that the consent must be "real and valid" — based on adequate information about the procedure and its material risks. The hospital must ensure that the unit transfused is sourced from a licensed blood bank, is correctly cross-matched, is within the validity period, and is administered under supervision. Where the chain of custody fails at the hospital end — the wrong unit is hung on the wrong patient, the unit is left at room temperature, the cross-match is omitted — the hospital's liability is on the Bolam-Jacob Mathew standard, parallel to and independent of the blood bank's strict liability.

The two layers can be cumulative. A patient who contracts hepatitis-C from a unit released without screening, transfused without cross-matching, on a clinical indication that did not require transfusion, has a claim against the blood bank on the strict-liability spine, against the hospital on the Bolam-Jacob Mathew standard for the cross-match failure, and against the doctor on the Bolam-Jacob Mathew standard for the un-indicated transfusion. Indian consumer forums have not been shy in allotting the burden among the three. Achutrao Haribhau Khodwa v State of Maharashtra, (1996) 2 SCC 634 — the swab-left-in-abdomen case — supplied the res ipsa loquitur route for the consumer-forum layer; where the cause of the infection is in the exclusive control of the hospital or the bank and the infection is one that would not, in the ordinary course, have happened without negligence, the forum may infer breach without affirmative expert evidence.

State liability and the writ route

Where the blood bank that released the infected unit is a state-run hospital, the patient has a fourth route open — a writ under Article 226, alleging violation of the Article 21 right to life and health, with a claim for monetary compensation under the public-law jurisdiction of the high court. The doctrinal anchor for state liability for tortious acts of state-run hospitals begins, paradoxically, with the pre-Constitution Bombay High Court decision in P&O Steam Navigation v Secretary of State, (1861) 5 Bom HCR App 1 — the case that introduced the sovereign-versus-non-sovereign-function distinction into Indian state-liability law. The distinction has been progressively eroded; the Supreme Court in Common Cause v Union of India itself, and in subsequent Article 21 health-rights cases, has treated the state as liable for the negligent acts of its hospitals on the same evidential basis as a private hospital, supplemented by the constitutional duty to ensure access to a regulated transfusion service.

The writ route is most attractive where the bank is state-run, the violation is structural (the bank was not licensed at all, the screening regime was not in place), and the relief sought is partly compensatory and partly directional — the Court can direct the state to upgrade the bank, to retrofit screening, to publish protocols, in addition to ordering compensation. The consumer-forum route is more attractive where the bank is private, the breach is specific to the unit released, and the relief sought is monetary. The civil-suit route is the residual route where the limitation period for the consumer forum has expired (the Limitation Act, 1963 supplies Article 113 — three years from the date the cause of action accrues, which in a transfusion-infection case is the date of knowledge of the infection, not the date of the transfusion). The criminal route — under Section 106(1) of the Bharatiya Nyaya Sanhita, 2023 [Section 304A IPC] where the patient has died, or under the special offences in Section 27 of the Drugs and Cosmetics Act, 1940 where the unit qualifies as a sub-standard drug — clears the gross-negligence threshold laid down in Jacob Mathew.

Compensation heads — Sarla Verma and Pranay Sethi

The compensation calculus in a transfusion-infection case, whether the patient has died or survived with chronic disease, draws on the Motor Vehicles Act compensation framework that the Supreme Court has progressively standardised for personal-injury and fatal-accident claims. Sarla Verma v Delhi Transport Corporation, (2009) 6 SCC 121 — a Constitution-Bench-affirmed three-Judge Bench decision in the Motor Vehicles context — laid down the structured multiplier method for fatal-accident compensation. The exercise begins with the deceased's "income" at the date of death, deducts personal-and-living expenses on a graduated scale that depends on the number of dependents, and multiplies the residue by an age-banded multiplier. National Insurance Co Ltd v Pranay Sethi, (2017) 16 SCC 680 — a Constitution Bench — added the "future prospects" head: a percentage uplift on the income to account for the salary increases the deceased would, on the actuarial probabilities, have received over a working life, with the percentage fixed by age and employment status. Pranay Sethi also standardised the conventional heads — loss of estate, loss of consortium, funeral expenses — at amounts that escalate every three years.

The Sarla Verma–Pranay Sethi framework has migrated, in working practice, from the MV Act jurisdiction into medical-negligence litigation. The National Consumer Disputes Redressal Commission and the Supreme Court in Balram Prasad v Kunal Saha, (2014) 1 SCC 384 — the AMRI Hospital case that produced the Rs 6.08 crore award for the death of Dr Kunal Saha's wife — applied a multiplier-style calculation to a medical-negligence death, expanding it for the loss of a high-earning professional. For a transfusion-infection case, the compensation heads work in two layers. Where the patient has died, the calculus is the Sarla Verma–Pranay Sethi calculation on the deceased's income, multiplier, future prospects, conventional heads, with an additional head for pain and suffering attributable to the period between infection and death. Where the patient has survived with chronic hepatitis-C, the calculus is loss of earning capacity (on the multiplier method for the residual earning years), medical expenses past and future (including antivirals, which for hepatitis-C now cost upwards of Rs 60,000 to Rs 1.5 lakh for a 12-week direct-acting antiviral regimen), pain and suffering, loss of amenities of life, and a separate head for loss of marriage prospects where the patient is unmarried at the date of infection. Where the patient has survived with HIV, the calculus includes the lifelong antiretroviral therapy expenses, the comorbidity-management expenses, and the social-loss heads.

What the framework produces — and what it does not

The doctrinal framework for transfusion-infection litigation in India is, as the case-law has worked itself out, a layered one. The strict-liability spine fastens on the blood bank's release of the unit. The Bolam-Jacob Mathew standard fastens on the treating doctor and the hospital. Schedule F Part XIIB and the NACO Standards supply the regulatory yardstick by which "due diligence" is judged. Common Cause supplies the constitutional anchor — that the Supreme Court itself built the architecture, and that operating outside it is operating against the directions of the Court. Sarla Verma and Pranay Sethi supply the compensation grid.

What the framework does not produce is a tariff. The same hepatitis-C transmission case can produce a Rs 5 lakh award before a District Commission with a thin evidential record and a Rs 30 lakh award before the National Commission with a full chain-of-custody reconstruction. The same HIV-transmission case can produce a Rs 10 lakh award where the bank is small and the unit is one of many transfused during a complex surgery, and a Rs 1 crore award where the bank is a major institution, the screening lapse is documented and the patient is a young earning professional with long working life ahead. The contested operational questions — whether the M C Mehta absolute-liability standard or the Rylands strict-liability standard applies to a blood bank, whether the donor-history defence survives Schedule F Part XIIB, whether the hospital and the bank can apportion liability where both have breached — continue to work themselves out before the consumer forums and the high courts.

For a researcher reading the cases the working takeaway is this. A transfusion that infects is not analysed as a medical-procedure case in the ordinary sense. It is analysed as the escape of a "drug" the law treats as inherently dangerous, with the blood bank on the strict-liability spine, the treating doctor and the hospital on the Bolam-Jacob Mathew standard, and the state on the Article 21 writ jurisdiction where the bank is state-run. The compensation heads are the Sarla Verma–Pranay Sethi heads, adapted for the long-tail medical and social losses of chronic transfusion-transmitted infection. The architecture is the architecture the Supreme Court built in Common Cause in 1996 — and the operating language is still the language of that judgment.